People
The People
Governance grade: B–. Tenet has a credibly independent board, a shareholder-friendly capital return record, and a pay-for-performance plan that actually paid out at maximum because results beat targets. But the same year saw the CEO collect $43M, the Board sign a fresh long-tenure employment agreement plus a special retention LTI grant, NEOs receive $11M of off-plan cash retention bonuses, and almost every named officer and several directors sell stock — with zero open-market buys. Combined Chairman/CEO and an aging Lead Director cap the upside.
Governance Grade
Skin-in-the-Game (1–10)
CEO : Median Worker
Institutional Ownership (%)
1. The People Running This Company
Five executives matter. The CEO is a former McKinsey senior healthcare partner promoted up from inside; the rest of the team was mostly built around him in 2023–2025. Notable: the COO role was created in May 2025, the CFO joined as an NEO only in 2024, and four of the five received special cash retention bonuses in May 2025 — meaning the bench is still being locked down.
Sutaria is the case here. He came from McKinsey, joined Tenet as COO in 2019, became CEO in September 2021, then assumed the Chairman role in August 2023 — an unusual three-year escalation. The amended employment agreement signed January 23, 2025 runs through end-2028 with auto-extensions, raised target bonus from 150% to 200% of base, and added a separately-granted retention LTI award not reflected in the standard target grant value table. He is competent and credible — Tenet's transformation around USPI, deleveraging, and divestitures happened on his watch — but Tenet has effectively front-loaded retention payments to keep him from leaving.
The accounting officer, Ramsey, having zeroed out his ownership twice within twelve months while still in role, is a small but real yellow flag.
2. What They Get Paid
CEO total compensation jumped 75% year-over-year, from $24.7M to $43.1M, the bulk of it from a $31.7M stock-award line that includes a one-time retention LTI grant tied to the new employment agreement. The board did this in the same year that 2023 long-term performance awards vested at 225% of target (the maximum possible) and 2025 annual bonuses paid at 200% of target. Pay was earned on the metrics — but the metrics were also reset upward in 2025.
Off-plan retention bonuses. In May 2025 the HR Committee paid one-time cash special recognition bonuses outside the AIP: $2M to Park, $4M each to Arnst and Foo, $1M to Arbour. They are clawed back if the executive resigns or is terminated for cause before May 2029 (May 2027 for Arbour). These sit on top of regular bonuses and stock awards and are the single biggest reason 2025 NEO totals jumped well above 2024.
The 2023 LTI awards vested in February 2026 at the maximum 225% of target: every annual tranche cleared the maximum threshold (Adj EPS $6.98/$11.88/$16.78; Adj FCF less NCI $1.18B/$0.59B/$1.84B), and Tenet placed first in three-year TSR against Community Health, HCA, and UHS, triggering the +25% multiplier. So the pay was earned. The concern is structural: the relative-TSR peer group is only three companies, with ranking-1 worth +25% and ranking-4 only -25% — a narrow, asymmetric benchmark that is easy to game with capital returns.
Pay ratio: 711-to-1. Median employee comp was $60,657; Sutaria $43.1M. Even adjusted out of the special retention LTI, the ratio remains in the 400s.
3. Are They Aligned?
This is the section that drives the verdict.
Ownership
Tenet has no founder, no promoter, no controlling holder. Insider ownership of all 16 officers and directors is 0.95% of shares outstanding (less than 1%). The shareholder register is dominated by passive index complexes.
Sutaria's 533,564 shares are worth roughly $127M at recent prices — meaningful in absolute dollars, but built almost entirely from compensation grants rather than purchases. The other officers each hold less than $10M.
Insider buying vs selling
There were no open-market insider purchases in the trailing twelve months. There were many open-market sales.
The single largest move: Sutaria sold 78,762 shares on September 10, 2025 for ~$15.0M at $190–192. The Form 4 contained no reference to a 10b5-1 plan. Three weeks earlier Foo sold $1.4M; in the same quarter every active NEO trimmed exposure post-RSU vest. After the February 2026 RSU vests, Arnst sold 32,000 shares for $7.5M, Arbour sold 6,500 for $1.5M, Ramsey sold the remainder of his entire stake for $1.9M.
This is the strongest negative governance signal in the file. Insiders are net sellers across every level of the org chart while paying themselves at maximum on every compensation lever.
Dilution and capital allocation
The capital-return record is the strongest positive offsetting the insider-selling concern:
Tenet repurchased $1.4B of stock in 2025 (8.8M shares) — well in excess of dilution from RSU vests and grants. The buyback is sized credibly relative to the $1.84B of adjusted FCF less NCI; it reduces share count net of insider liquidations. No dividend is paid; capital returns are 100% buyback.
Related-party behavior
The proxy discloses no related-party transactions of consequence between Tenet and its officers or directors. Director Agarwala's a16z fund invests in healthcare technology that could create conflicts; the proxy notes none rose to the disclosure threshold. No officer or director has pledged any shares of common stock — a clean positive.
Skin-in-the-game score
Skin-in-the-Game Score
A 4/10. Sutaria has real dollar exposure ($127M of stock) and is on an employment agreement through 2028 with retention equity, so he is locked in. But the ownership came from compensation, not personal investment, and the trailing twelve months of insider flow is uniformly outbound. Other executives hold trivial amounts net of tax-withholding sales and have just been paid $11M of cash retention bonuses to stay, suggesting management thinks the optimal way to keep its team is contractually rather than through equity alignment. The capital-return record (and the absence of pledges) is what keeps this from being lower.
4. Board Quality
Twelve directors. Eleven independent. The CEO is the only insider. The board is functionally diversified across healthcare operating, regulatory/policy, finance/audit, and military/risk experience — but it is also old: four directors are 73 or older, including the Lead Director.
The committee chairs are credible: Romo chairs Audit (former Southwest CFO; experienced public-company audit chair via Ryder), Kerrey chairs HR (long Senate / governor career, plus Allen & Co), FitzGerald chairs Nominating/Governance (Columbia, multiple healthcare boards), Bierman chairs Quality, Compliance & Ethics (former Owens & Minor CEO/CFO). All four had committee experience before joining their current chair roles.
The structural weaknesses:
Combined Chairman + CEO. Sutaria has held both roles since August 2023. The independent Lead Director is 82-year-old Senator Bob Kerrey. Kerrey is also chair of the HR Committee — meaning the same person who decides CEO pay also runs the closest formal check on the CEO. Even with strong individual quality, the structure concentrates oversight in one independent director.
Aging board. Four directors are 73+ (Kerrey 82, Fisher 77, Blunt 76, Bierman 73). There is no disclosed retirement age policy, and three of these four chair or co-chair a major committee. Succession on the board itself, not just management, is a near-term issue.
The Audit Committee report and the absence of any disclosed material weakness, restatement, or reportable governance lapse are positives. The board met its 75% attendance standard for every director in 2025.
5. The Verdict
Final Governance Grade
Grade: B–.
The strongest positives. Eleven of twelve directors are genuinely independent, with deep individual credentials. The pay plan paid for performance: 2023 LTI vested at the maximum 225% of target only because adjusted EPS, FCF, and three-year TSR cleared every threshold. $1.4B was returned to shareholders via buyback in 2025 — a ratio that reduces share count net of all insider grants and sales. No pledged shares. No related-party transactions. No founder or controlling holder; one share, one vote.
The real concerns. CEO and Chairman are the same person, and the independent Lead Director who would otherwise check that combination is 82 and chairs the committee that sets his pay. The 2025 CEO package of $43M was 75% larger than 2024, partly because the board signed a fresh 2025–2028 employment agreement with a separate retention LTI grant on top of the regular plan; in the same year, four NEOs received $11M of cash retention bonuses outside the regular plan. While all of that was happening, the CEO sold $15M of stock in a single September transaction with no 10b5-1 disclosure, and every other named officer was a net seller. Pay-for-performance is real, but the levers are narrow: the relative-TSR benchmark is only three peers, and 2023 awards vested at the cap on every dimension.
The single thing most likely to upgrade. Splitting the Chair and CEO roles, or rotating in a younger Lead Director with no role on HR Comp, would move this to a clean B+ very quickly.
The single thing most likely to downgrade. Another quarter of heavy open-market insider selling — particularly any unscheduled CEO sale — combined with any quality-of-care or compliance event that surfaces in the QCE Committee disclosures, would push this to C+.